Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | HTR2C | P28335 | 2/20 | 0.64 |
| ▸ | HRH1 | P35367 | 2/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | DRD3 | P35462 | 2/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.64 |
| ▸ | HTR2B | P41595 | 2/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | KLF10 | Q13118 | 2/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12546966 | 0.90 | SLC6A2 (0.67) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12546930 | 0.83 | SLC6A2 (0.44) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL4730875 | 0.81 | SLC6A4 (0.86) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL5011175 | 0.81 | SLC6A4 (0.86) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL4082557 | 0.81 | SLC6A4 (0.86) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5280203 | 0.81 | SLC6A2 (0.64) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14525280 | 0.80 | CYP1A2 (0.40) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL341802 | 0.78 | SLC6A4 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL5783906 | 0.78 | SLC6A4 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL12047445 | 0.78 | SLC6A4 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| EP-1951643-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2007062119-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062119-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | SLC6A2 5/4885SLC6A4 1/4885CYP1A2 1159/4885 |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | SLC6A2 5/4885SLC6A4 1/4885CYP1A2 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.